KIR2DL3 and hepatocellular carcinoma: In addition, KIR2DS2high NK cells from HCC patients had enhanced activation against HLA-deficient 721.221 target cells both in the absence and presence of the type II anti-CD20 mAb obinutuzumab (p<0.01) compared to KIR2DL3/L2high and KIR2DL3/L2/S2- NK cells (Figures 1I, J).